

SIGA TECHNOLOGIES INC
 Form 4/A
 October 22, 2010

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 MJALLI ADNAN M M

(Last) (First) (Middle)

C/O TRANSTECH PHARMA,
 INC., 4170 MENDENHALL OAKS
 PARKWAY, SUITE 110

(Street)

HIGH POINT, NC 27265

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 SIGA TECHNOLOGIES INC
 [SIGA]

3. Date of Earliest Transaction
 (Month/Day/Year)
 09/30/2009

4. If Amendment, Date Original Filed(Month/Day/Year)
 10/02/2009

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	Price	
Common Stock, par value \$0.0001 per share ("Common Stock")	09/30/2009		X		1,845,396	A \$ 1.8784	4,317,618 I by TransTech Pharma, Inc. ⁽²⁾
Common Stock	09/30/2009		F		444,666	D \$ 7.8	3,872,952 I by TransTech Pharma,

Common Stock	09/30/2009	S	3,851,969 (1)	D	\$ 6.24	20,983	I	Inc. (2) by TransTech Pharma, Inc. (2)
--------------	------------	---	------------------	---	---------	--------	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount Number Shares
Warrant (right to buy)	\$ 1.8784	09/30/2009		X	1,845,396	01/08/2004 01/08/2011	Common Stock 1,845,396

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MJALLI ADNAN M M C/O TRANSTECH PHARMA, INC. 4170 MENDENHALL OAKS PARKWAY, SUITE 110 HIGH POINT, NC 27265	X	X		

Signatures

Adnan M. M. 10/22/2010
Mjalli

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1)

Edgar Filing: SIGA TECHNOLOGIES INC - Form 4/A

On September 30, 2009, TransTech Pharma, Inc. sold 3,851,969 shares of Common Stock in a privately negotiated transaction to STH Partners, L.P.

- (2) The shares of Common Stock and the warrants were beneficially owned by TransTech Pharma, Inc. The reporting person is the President, Chief Executive Officer and a director of TransTech Pharma, Inc. The reporting person disclaims beneficial ownership of the securities beneficially owned by TransTech Pharma, Inc. except to the extent of his pecuniary interest therein.

Remarks:

This amendment is filed to restate the original Form 4. The number of shares shown in this restated Form 4 reflects an anti-dilution

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.